Quantcast

Latest cardiovascular disease Stories

2014-09-17 08:30:11

- Up to $200 Million Collaboration to Support Pioneering Science and New Treatments - PARIS and SOUTH SAN FRANCISCO, Calif., Sept. 17, 2014 /PRNewswire/ -- Sanofi (EURONEXT: SAN and NYSE: SNY) and MyoKardia, Inc., a privately-held company leading the development of precision therapies for genetic heart disease, announced today a worldwide collaboration to discover and develop first-of-its-kind targeted therapeutics for heritable heart diseases known as cardiomyopathies, the most...

2014-09-17 08:28:32

ZUG, Switzerland, Sept. 17, 2014 /PRNewswire/ -- Cardiorentis AG, a privately held biopharmaceutical company, today announced that it has entered into a EUR45 million financing agreement with HealthCare Royalty Partners ("HC Royalty"), a U.S. based healthcare investment firm. The proceeds will be used to finance the Company's registration program for the natriuretic peptide Ularitide in acute heart failure. "This is a pivotal time for our Company. The team at HC Royalty understood...

2014-09-15 20:21:56

WOODBRIDGE, ON, Sept. 15, 2014 /PRNewswire/ - Pivotal Therapeutics Inc. (OTCQX:PVTTF; CSE:PVO), ("Pivotal" or the "Company"), a specialty pharmaceutical company with a focus on Omega-3 therapies for cardiovascular disease and overall health, announced today that the Board of Directors approved the granting of stock options to an officer and an advisor at the close of business on Friday, September 12, 2014. Options to acquire a total of 1,000,000 common shares of the Company were...

2014-09-15 12:27:22

Tiara(TM) Transcatheter Mitral Valve program featured in multiple scientific presentations NASDAQ: NVCNTSX: NVC WASHINGTON, DC, Sept. 15, 2014 /PRNewswire/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ: NVCN) (TSX: NVC) announced today that its Reducer(TM) technology was featured in a "live case" broadcast on Sunday, September 14, 2014 at the 26th Annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium. A Clinical update on the company's Tiara(TM)...

2014-09-10 16:26:00

WOODBRIDGE, ON, Sept. 10, 2014 /PRNewswire/ - Pivotal Therapeutics Inc. (OTCQX:PVTTF; CSE:PVO), ("Pivotal" or the "Company"), a specialty pharmaceutical company with a focus on Omega-3 therapies for cardiovascular disease ("CVD") and overall health, announced today the publication of results of a prospective randomized controlled trial in the U.S. that evaluated the effects of VASCAZEN(®) in the correction of Omega-3 deficiency in patients with one or more risk factors associated...

2014-09-10 08:32:05

Data Will Focus on Areas of Significant Unmet Patient Need, Including Coronary Artery Disease and Aortic Valve Disease MARLBOROUGH, Mass., Sept. 10, 2014 /PRNewswire/ -- Beginning Saturday, Boston Scientific Corporation (NYSE: BSX) will present data that reinforce the company's commitment to advancing science for life and to developing innovative therapies in interventional cardiology. The company will share results from more than a dozen clinical studies at the 26th Transcatheter...

2014-09-09 23:15:05

A man’s likelihood of accumulating fat around his heart – an important indicator of heart disease risk – may be better determined if doctors consider his race and ethnicity, as well as where on his body he’s building up excess fat, reveals an international evaluation led by the University of Pittsburgh Graduate School of Public Health. Pittsburgh, PA (PRWEB) September 09, 2014 A man’s likelihood of accumulating fat around his heart – an important indicator of heart disease...

2014-09-09 23:12:35

According to Neuropsychologist Dr. Kenneth Freundlich with Morris Psychological Group one side effect that is just beginning to be understood is that heart disease has consequences for thinking and communication. Parsippany, NJ (PRWEB) September 09, 2014 As medical intervention and treatment have improved and as people have become more conscientious about lifestyle factors that improve heart health, deaths from heart disease have declined. According to the American Heart Association,...

2014-09-09 23:03:04

Soulati Will Address How to Prevent and Reverse Cardiovascular Disease with Her Lifestyle Modification Program, the Sara Soulati Health for Life Program, Combined with Enhanced External Counterpulsation (EECP) Los Angeles, CA (PRWEB) September 09, 2014 Sara Soulati, CEO and Founder of Global Cardio Care, is presenting a lecture to seniors at Crenshaw Christian Center in Los Angeles at 10 a.m. on Sept. 11, 2014. A clinical team will attend and offer advice on regular screenings to monitor...

2014-09-08 12:29:37

WOODBRIDGE, ON, Sept. 8, 2014 /PRNewswire/ - Pivotal Therapeutics Inc. (OTCQX:PVTTF; CSE:PVO), ("Pivotal" or the "Company"), a specialty pharmaceutical company with a focus on Omega-3 therapies for cardiovascular disease ("CVD") and overall health, today announced the appointment of Prakash Gowd as the Company's Chief Financial Officer. Mr. Gowd succeeds Eugene Bortoluzzi, who will remain Pivotal's Chief Executive Officer. In addition to having an impressive track record as one...


Latest cardiovascular disease Reference Libraries

Circulation (journal)
2012-06-04 14:21:01

Circulation is a scientific journal published by Lippincott Williams & Wilkins on behalf of the American Heart Association. In 2008 the journal added six subspecialty publications: Circulation: Arrhythmia and Electrophysiology, Circulation: Heart Failure, Circulation: Cardiovascular Imaging, Circulation: Cardiovascular Interventions, Circulation: Cardiovascular Quality and Outcomes, and Circulation: Cardiovascular Genetics. Circulation publishes articles related to research in and the...

More Articles (1 articles) »
Word of the Day
omadhaun
  • A fool; a simpleton: a term of abuse common in Ireland and to a less extent in the Gaelic-speaking parts of Scotland.
This word is partly Irish in origin.